ea0041ep538 | Diabetes therapy | ECE2016
Silko Iuliia
, Nikonova Tatiana
, Shestakova Marina
Introduction: LADA exhibits characteristics of both type 1 diabetes mellitus (DM) and type 2 DM. Patients with LADA usually have some components of metabolic syndrome. GLP-1 agonists have been widely used in type 2 DM. GLP-1 agonist therapies have shown some promising glucose lowering effect in T1DM. Almost no information is available on glucagon and incretin secretion in patients with LADA as well as effects on glucose and C-peptide levels.Case report: ...